文献速递神经肿瘤

强效PI3K与MAPK抑制剂联合治疗克服胶质母细胞瘤临床前模型中对单药的适应性激酶组耐药

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.
PubMed 文献 · Neuro Oncol · 2017-01-01

在胶质母细胞瘤(GBM)小鼠模型及患者来源异种移植模型中,PI3K与MEK抑制剂的效力与靶点抑制、替代RTK效应器激活及疗效相关。双PI3K/MEK抑制在体外协同并克服替代通路激活,皮下同种移植中优于单药,但原位同种移植中疗效有限,可能因剂量限制性毒性与靶点抑制不完全。

要点

  • PI3K与MEK抑制剂效力与靶点抑制、替代RTK效应器激活及疗效直接相关。
  • GBM患者来源异种移植与肿瘤样本激酶组异质,部分后者存在MAPK过度激活。
  • 双PI3K/MEK抑制在体外协同,皮下同种移植中优于单药,但原位同种移植疗效有限。

核心结论

  • 药物效力影响PI3K/MEK抑制剂诱导的靶点抑制、适应性激酶组重编程、疗效与协同作用。
  • 研究结果提示,需要采用高效、脑渗透性激酶抑制剂的联合治疗来改善患者结局。

研究设计与样本

  • 研究使用永生化的星形胶质细胞中通过Pten缺失与KrasG12D激活PI3K和MAPK的非生殖系基因工程小鼠GBM模型。
  • 在此模型中检查药物效力对靶点抑制、替代通路激活、疗效及单药与联合治疗协同作用的影响。
  • 随后在GBM患者来源异种移植(PDX)中体外和体内检查疗效。

主要发现

  • 在体外突变型小鼠星形胶质细胞中,PI3K与MEK抑制剂效力与靶点抑制、替代RTK效应器激活及疗效直接相关。
  • GBM PDX与肿瘤样本的激酶组呈异质性,部分后者存在MAPK过度激活。
  • 双PI3K/MEK抑制剂治疗克服替代效应器激活,体外协同,在皮下小鼠同种移植中比单药治疗更有效。
  • 然而,原位同种移植中疗效极小,可能由于剂量限制性毒性与靶点抑制不完全。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原位同种移植中疗效极小,可能由于剂量限制性毒性与靶点抑制不完全。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Prognosis remains poor despite multimodal therapy. Developing alternative treatments is essential. Drugs targeting kinases within the phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) effectors of receptor tyrosine kinase (RTK) signaling represent promising candidates. METHODS: We previously developed a non-germline genetically engineered mouse model of GBM in which PI3K and MAPK are activated via Pten deletion and KrasG12D in immortalized astrocytes. Using this model, we examined the influence of drug potency on target inhibition, alternate pathway activation, efficacy, and synergism of single agent and combination therapy with inhibitors of these 2 pathways. Efficacy was then examined in GBM patient-derived xenografts (PDX) in vitro and in vivo. RESULTS: PI3K and mitogen-activated protein kinase kinase (MEK) inhibitor potency was directly associated with target inhibition, alternate RTK effector activation, and efficacy in mutant murine astrocytes in vitro. The kinomes of GBM PDX and tumor samples were heterogeneous, with a subset of the latter harboring MAPK hyperactivation. Dual PI3K/MEK inhibitor treatment overcame alternate effector activation, was synergistic in vitro, and was more effective than single agent therapy in subcutaneous murine allografts. However, efficacy in orthotopic allografts was minimal. This was likely due to dose-limiting toxicity and incomplete target inhibition. CONCLUSION: Drug potency influences PI3K/MEK inhibitor-induced target inhibition, adaptive kinome reprogramming, efficacy, and synergy. Our findings suggest that combination therapies with highly potent, brain-penetrant kinase inhibitors will be required to improve patient outcomes.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. McNeill RS, Canoutas DA, Stuhlmiller TJ, et al. Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro Oncol. 2017. PMID: 28379424. doi:10.1093/neuonc/nox044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。